Preferred Label : Mecbotamab Vedotin;
NCIt synonyms : CAB Anti-AXL ADC BA3011; ADC BA3011; CAB-AXL-ADC BA3011; Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011;
NCIt definition : An antibody-drug conjugate (ADC) composed of a conditionally active biologic (CAB)
antibody against AXL receptor tyrosine kinase (AXL; UFO) conjugated to an as of yet
undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration
of mecbotamab vedotin, the anti-AXL antibody becomes activated through an as of yet
not fully elucidated process only under the unique microphysical conditions that are
present in the tumor microenvironment (TME) as a result of the glycolytic metabolism
of cancer cells, and not in the microenvironment of normal, healthy tissues. Upon
selective binding to AXL-expressing tumor cells and internalization, the cytotoxic
agent kills the tumor cells through an as of yet undisclosed mechanism of action (MoA).
AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases
normally expressed on many normal, healthy cells and overexpressed by many tumor cell
types, plays a key role in tumor cell proliferation, survival, invasion and metastasis;
its expression is associated with drug resistance and poor prognosis. The CAB antibody
allows for efficient and reversible binding to AXL-expressing tumor cells under conditions
that are present only in the TME, thereby maximizing efficacy while minimizing toxicity
by avoiding activation and thus binding of the antibody to normal, healthy AXL-expressing
cells under normal conditions.;
UNII : VF40YVX65F;
CAS number : 2460400-64-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2460400-64-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : BA-3011; BA 3011;
NCI Metathesaurus CUI : CL562853;
Origin ID : C156141;
UMLS CUI : C5575128;
Semantic type(s)
- concept_is_in_subset
- has_target
